We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Testosterone & Perimenopause · All 50 States
Testosterone for women compared with estrogen-first therapy: what the randomized evidence supports (low sexual desire), what it does not, dosing routes, monitoring, and why no FDA-approved female product exists in the U.S.
Start your visit — $79/mo →← Hormone replacement therapy pillar
DIRECT ANSWER
The only indication with consistent randomized evidence for testosterone in women is hypoactive sexual desire disorder after menopause, and only after estrogen therapy has been optimized. The 2019 Global Consensus Position Statement supports physiologic-dose testosterone for that indication and does not support it for fatigue, mood, cognition, bone, or body composition. There is no FDA-approved female testosterone product in the United States, so prescribing is off-label with careful dose control and monitoring.
| Option | Route | Typical dose | Best suited to | Trade-off |
|---|---|---|---|---|
| Compounded transdermal testosterone cream | Daily to skin | Physiologic female dosing, individualized | Persistent low desire with distress after estrogen is optimized | Compounded; dose consistency and monitoring matter |
| Off-label use of an approved male gel (fractional dose) | Daily to skin | A fraction of the male dose | Access when compounding is impractical | Dosing error risk; transfer to partners and children |
| Estrogen therapy first | Patch, gel, or oral | Standard HRT dosing | Most desire complaints tied to vaginal dryness, pain, sleep loss, or vasomotor symptoms | Does not directly address androgen-mediated desire in a minority of women |
| Vaginal estrogen or DHEA | Local | 10 mcg insert; 6.5 mg prasterone | When pain, not desire, is the primary driver | Local effect only |
| Testosterone pellets or injections | Implanted or injected | Supraphysiologic in common practice | Not recommended for women | Unpredictable levels, supraphysiologic exposure, irreversible virilizing effects |
Doses shown are typical starting ranges for context only. Your clinician sets your dose based on your history.
The randomized evidence does not support testosterone for fatigue, mood, or cognition in women. Those symptoms are usually better addressed by treating estrogen deficiency, sleep disruption, iron or thyroid abnormalities, and depression directly.
Not in the United States. Prescribing is off-label, which makes physiologic dosing, informed consent, and monitoring essential.
The consensus evidence base is postmenopausal. In perimenopause, cycle irregularity and fluctuating estradiol are usually the dominant drivers, so clinicians typically stabilize estrogen and progesterone first.
They produce higher and less controllable levels, not better outcomes. Major guideline bodies advise against pellets and injections for women.
A board-certified clinician licensed in your state reviews your intake within one business day and recommends the route that fits your history — not a template.
Start your visit — $79/mo →Comparing providers first? How to choose an HRT telehealth provider →
WRITTEN & MEDICALLY REVIEWED BY
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
Kindr’s clinical content is written and reviewed by board-certified clinicians who prescribe hormone therapy every day across all 50 states — menopause-focused physicians, nurse practitioners, and pharmacists working under Kindr Health, Inc.’s organizational clinical oversight. Every page is checked against current NAMS and ACOG guidance, FDA labeling, and the primary literature before publication, then re-reviewed on a rolling schedule when guidance changes.
Organizational NPI 1609792902 · Last reviewed July 3, 2026 · Editorial policy
Educational content only — not a substitute for individual medical advice, diagnosis, or treatment.
SOURCES & REFERENCES
Information on this page is for educational purposes only. Prescription medications require clinical evaluation and provider approval. Individual results vary. Not an emergency service.